SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal ...
Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development SANTA CLARA, Calif. & ...
Two companies will provide an end-to-end solution tailored to application services. Oxford Gene Technology (OGT) and Agilent Technologies completed a collaborative agreement giving OGT access to ...
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx ...
Agilent’s SurePrint microarray technology features a flexible, industrial-scale inkjet printing process that synthesizes oligonucleotide probes in situ onto 1“ x 3“ slides. The maskless process allows ...
The State of the Microarray | Selected Suppliers of Microarray Chips, Spotters, and Readers Courtesy of Amersham Biosciences Note: a = arrays; r = reader; s = spotter Affymetrix www.affymetrix.com - a ...
Agilent Technologies Inc. has announced the extension of its technology access program to National Cancer Institute (NCI) extramural researchers. The NCI funds approximately 4,500 research grants a ...
Agilent Technologies Inc. has announced it has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc. for the manufacture, marketing and sale of oligonucleotide microarrays using ...
Microarrays, including genome tiling microarrays, are exceptionally powerful tools for querying diverse genomic features, including mapping gene expression and structure, analyzing polymorphisms, ...
When Baylor College of Medicine (BCM) researcher Jennifer Lee was studying the mechanisms of Pelizaeus-Merzbacher disease (PMD), she expected to find DNA additions or deletions in the wrong place on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results